- Home
- BLNK vs GANX Comparison
BLNK vs GANX Comparison
Compare BLNK & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLNK | GANX |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.9M | 78.2M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BLNK | GANX |
|---|---|---|
| Price | $0.83 | $2.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $1.95 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 2.5M | 533.8K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.22 | 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $126,197,000.00 | $55,180.00 |
| Revenue This Year | $5.71 | N/A |
| Revenue Next Year | $19.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $1.41 |
| 52 Week High | $2.65 | $4.34 |
Technical Indicators
Market Signals| Indicator | BLNK | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 68.40 | 49.02 |
| Support Level | $0.63 | $1.55 |
| Resistance Level | $0.97 | $2.09 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 91.91 | 62.57 |
Price Performance
Historical ComparisonAbout BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.